COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on COMPASS Pathways today and set a price target of $65.00. Trucchio covers the He...

H.C. Wainwright Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on COMPASS Pathways (CMPS), Ocugen (OCGN) and Disc Medi...

Analysts Are Bullish on These Healthcare Stocks: COMPASS Pathways (CMPS), Ocugen (OCGN)

Compass Pathways Plc ($CMPS) announced an update on their ongoing clinical study. The Redefine Study is a late-stage trial run by COMPASS Pathways ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CMPS	$13.06	-0.23%	2.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CMPS	$13.06	-0.2%	2.23M
3
4
5
6

CMPS

Get COMPASS Pathways plc Data in Excel

Get COMPASS Pathways plc Data in Excel